COCONUT CREEK, FL – 
According to Grand View Research, the global CBD market is projected to grow from $2.8 billion in 2020 to $13.4 billion in 2028, representing a 21.2% compound annual growth rate. Meanwhile, the analyst believes that the industrial hemp market will grow at a comparable 16.2% CAGR to reach $12.1 billion by 2028.
“NutraLife is a leading manufacturer of ingestible and skincare products using breakthrough, nutrient-rich formulations with the most effective ingredients and delivery systems available in the nutraceuticals industry,” said NutraLife CEO Edgar Ward.
In conjunction with recent private-label agreements, the Company is in the process of expanding its manufacturing operations and capabilities to accommodate the production of several new products expected to be released in the near future. These products include NLBS’s immune booster drink shot infused with CBDA. CBDA along with CGBA have been found to “bind to the SARS-CoV-2 spike protein, blocking a critical step in the process the virus uses to infect people.” Steve Lundeberg, Oregon State University.
NutraLife is also preparing an application for a planned uplisting to the OTCQB, with the objectives of increasing its visibility and exposure within the North American financial community, and creating additional value for shareholders.
“It’s an exciting time for NutraLife shareholders as we announce new partnership agreements with industry leaders and scale up operational capacity to expand our in-house product line-up,” added Mr. Ward.
About NutraLife Biosciences, Inc.
NutraLife BioSciences, Inc. operates a multifaceted life sciences and lifestyle health and wellness manufacturing company. For more than ten years, NutraLife has manufactured and distributed both private label and branded nutraceutical and skincare wellness products.
For more information, visit our website at www.nutralifebiosciences.com.
NutraLife BioSciences, Inc.
6601 Lyons Road, Suite L-6
Coconut Creek, FL 33073
Telephone 888-509-8901
Forward-Looking Statements
This press release contains statements of a forward-looking nature about NutraLife Biosciences, Inc. (the “Company”). You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements primarily on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on the Company’s information on the date hereof. These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors is set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on June 24, 2021. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.